Review



cell carcinoma cell lines  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC cell carcinoma cell lines
    Cell Carcinoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 247 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell carcinoma cell lines/product/ATCC
    Average 96 stars, based on 247 article reviews
    cell carcinoma cell lines - by Bioz Stars, 2026-03
    96/100 stars

    Images



    Similar Products

    cell carcinoma cell lines  (ATCC)
    96
    ATCC cell carcinoma cell lines
    Cell Carcinoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell carcinoma cell lines/product/ATCC
    Average 96 stars, based on 1 article reviews
    cell carcinoma cell lines - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    caki  (ATCC)
    96
    ATCC caki
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O <t>and</t> <t>Caki-1</t> cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Caki, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/caki/product/ATCC
    Average 96 stars, based on 1 article reviews
    caki - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    caki 2  (ATCC)
    96
    ATCC caki 2
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O <t>and</t> <t>Caki-1</t> cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Caki 2, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/caki 2/product/ATCC
    Average 96 stars, based on 1 article reviews
    caki 2 - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    caki 1 cells  (ATCC)
    96
    ATCC caki 1 cells
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O <t>and</t> <t>Caki-1</t> cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Caki 1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/caki 1 cells/product/ATCC
    Average 96 stars, based on 1 article reviews
    caki 1 cells - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    metastatic ccrcc cell line  (ATCC)
    96
    ATCC metastatic ccrcc cell line
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O <t>and</t> <t>Caki-1</t> cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Metastatic Ccrcc Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/metastatic ccrcc cell line/product/ATCC
    Average 96 stars, based on 1 article reviews
    metastatic ccrcc cell line - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    human clear cell renal carcinoma ccrcc cell line caki  (ATCC)
    96
    ATCC human clear cell renal carcinoma ccrcc cell line caki
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O <t>and</t> <t>Caki-1</t> cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Human Clear Cell Renal Carcinoma Ccrcc Cell Line Caki, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human clear cell renal carcinoma ccrcc cell line caki/product/ATCC
    Average 96 stars, based on 1 article reviews
    human clear cell renal carcinoma ccrcc cell line caki - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    bbb: blood-brain barrier caki-2  (ATCC)
    96
    ATCC bbb: blood-brain barrier caki-2
    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O <t>and</t> <t>Caki-1</t> cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.
    Bbb: Blood Brain Barrier Caki 2, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bbb: blood-brain barrier caki-2/product/ATCC
    Average 96 stars, based on 1 article reviews
    bbb: blood-brain barrier caki-2 - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.

    Journal: Cancer Genomics & Proteomics

    Article Title: Timescale-dependent Phosphoproteomic Remodeling and Motility-associated Adaptation under Chronic Cabozantinib Exposure in Renal Cell Carcinoma

    doi: 10.21873/cgp.20576

    Figure Lengend Snippet: Growth‑inhibitory effect of cabozantinib. (A) Dose-response cell viability after 48 h cabozantinib treatment in 786-O and Caki-1 cells. Values represent mean ± standard deviation (SD) (n=4); *p<0.01 vs. vehicle. (B) Immunoblot analysis of total MET and phospho-MET (Y1234/1235) in parental (Par) and chronically treated (Chr) cells, with or without cabozantinib treatment. Cabozantinib robustly suppressed phospho-MET in both Par and Chr states of both cell lines. β-actin serves as a loading control. (C) Time-course viability (24-72 h) of Par and Chr 786-O cells. (D) Time-course viability (24-72 h) of Par and Chr Caki-1 cells. Cab: acute cabozantinib-treated; Par: parental; Chr: chronically cabozantinib-treated cells (>4 months). *p<0.05; **p<0.01. Statistical significance was determined using an unpaired two-tailed Student’s t-test.

    Article Snippet: Parental 786-O and Caki-1 renal cell carcinoma cell lines were obtained from ATCC (Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere containing 5% CO 2 .

    Techniques: Standard Deviation, Western Blot, Control, Two Tailed Test